Verici Dx (FRA:63V) Return-on-Tangible-Asset: -186.80% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Verici Dx Return-on-Tangible-Asset?

Verici Dx FRA:63V -20.00% Return-on-Tangible-Asset is -186.80% as of Dec. 2025. The stock has 3 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Verici Dx ranks worse than 90.14% on this metric.

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Verici Dx's annualized Net Income for the quarter that ended in Dec. 2025 was €-6.56 Mil. Verici Dx's average total tangible assets for the quarter that ended in Dec. 2025 was €3.51 Mil. Therefore, Verici Dx's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was -186.80%.

The historical rank and industry rank for Verici Dx's Return-on-Tangible-Asset or its related term are showing as below:

FRA:63V' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -148.71   Med: -98.65   Max: -55.3
Current: -148.71

During the past 6 years, Verici Dx's highest Return-on-Tangible-Asset was -55.30%. The lowest was -148.71%. And the median was -98.65%.

FRA:63V's Return-on-Tangible-Asset is ranked worse than
90.14% of 213 companies
in the Medical Diagnostics & Research industry
Industry Median: -2.4 vs FRA:63V: -148.71

Verici Dx  (FRA:63V) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Verici Dx Return-on-Tangible-Asset Related Terms


Verici Dx Return-on-Tangible-Asset Historical Data

* Premium members only.

The historical data trend for Verici Dx's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Verici Dx Return-on-Tangible-Asset Chart

Verici Dx Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Return-on-Tangible-Asset
Get a 7-Day Free Trial -57.44 -97.58 -96.77 -111.23 -116.96

Verici Dx Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -108.88 -35.22 -119.32 -147.58 -186.80

FRA:63V vs TMO, DHR, IDXX: Return-on-Tangible-Asset Comparison

For the Diagnostics & Research subindustry, Verici Dx's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verici Dx Return-on-Tangible-Asset vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Verici Dx's Return-on-Tangible-Asset falls into.



Verici Dx Return-on-Tangible-Asset Calculation

Verici Dx's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-5.921/( (5.179+4.946)/ 2 )
=-5.921/5.0625
=-116.96 %

Verici Dx's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-6.564/( (2.082+4.946)/ 2 )
=-6.564/3.514
=-186.80 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.

What does a Return-on-Tangible-Asset of -186.80% mean?
Verici Dx (FRA:63V) has a Return-on-Tangible-Asset of -186.80% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Verici Dx and its competitors. According to the industry distribution chart, Verici Dx ranks #192 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 90.1%.
Is Verici Dx's Return-on-Tangible-Asset too high?
Verici Dx's current Return-on-Tangible-Asset is -186.80%. Based on the distribution chart, Verici Dx ranks #192 out of 213 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Verici Dx's Return-on-Tangible-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Verici Dx ranks #192 out of 213 companies for Return-on-Tangible-Asset. This places Verici Dx in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Asset depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Verici Dx and its competitors. Verici Dx's current Return-on-Tangible-Asset is -186.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verici Dx stock overvalued right now?
Verici Dx (FRA:63V) has a current Return-on-Tangible-Asset of -186.80%. The current Return-on-Tangible-Asset is -186.80%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Verici Dx (FRA:63V), the current Return-on-Tangible-Asset is -186.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Verici Dx Business Description

Other Exchanges VRCI:UK
Address 19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on the development of prognostic and diagnostic tests for kidney transplant patients. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; Tuteva, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels; and Protega will utilize RNA gene signatures to more accurately risk stratify outcome from fibrosis in a transplant patient. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.